Kenvue Inc. (NYSE:KVUE) Given Consensus Recommendation of “Hold” by Brokerages

Kenvue Inc. (NYSE:KVUE) has been given a consensus rating of “Hold” by the thirteen brokerages that are presently covering the stock, MarketBeat.com reports. Eight analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $24.42.

KVUE has been the topic of a number of research analyst reports. Piper Sandler raised their price objective on shares of Kenvue from $24.00 to $27.00 and gave the company an “overweight” rating in a research note on Monday, February 24th. Evercore ISI started coverage on Kenvue in a research note on Monday, March 24th. They issued an “in-line” rating and a $25.00 price objective on the stock. UBS Group cut their price objective on Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a report on Friday, February 7th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $24.00 target price on shares of Kenvue in a report on Monday, February 3rd. Finally, Barclays cut their price target on shares of Kenvue from $23.00 to $22.00 and set an “equal weight” rating for the company in a report on Monday, April 14th.

Kenvue Stock Up 0.5 %

Shares of Kenvue stock opened at $23.12 on Tuesday. Kenvue has a 1-year low of $17.67 and a 1-year high of $24.46. The company has a market capitalization of $44.36 billion, a P/E ratio of 43.62, a PEG ratio of 2.62 and a beta of 1.02. The business’s fifty day moving average price is $23.04 and its two-hundred day moving average price is $22.46. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69.

Kenvue (NYSE:KVUE) last issued its quarterly earnings data on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. As a group, research analysts forecast that Kenvue will post 1.14 EPS for the current year.

Kenvue Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, May 28th. Investors of record on Wednesday, May 14th will be paid a dividend of $0.205 per share. The ex-dividend date is Wednesday, May 14th. This represents a $0.82 annualized dividend and a yield of 3.55%. Kenvue’s dividend payout ratio is 154.72%.

Institutional Trading of Kenvue

A number of hedge funds have recently modified their holdings of KVUE. Mutual Advisors LLC raised its stake in shares of Kenvue by 5.7% in the first quarter. Mutual Advisors LLC now owns 15,994 shares of the company’s stock valued at $368,000 after purchasing an additional 867 shares in the last quarter. Oregon Public Employees Retirement Fund lifted its holdings in shares of Kenvue by 0.9% during the 1st quarter. Oregon Public Employees Retirement Fund now owns 165,746 shares of the company’s stock worth $3,975,000 after acquiring an additional 1,400 shares during the period. Teacher Retirement System of Texas boosted its position in shares of Kenvue by 62.6% during the 1st quarter. Teacher Retirement System of Texas now owns 501,448 shares of the company’s stock valued at $12,025,000 after acquiring an additional 192,981 shares in the last quarter. Revisor Wealth Management LLC bought a new stake in Kenvue in the first quarter valued at about $472,000. Finally, Alley Investment Management Company LLC raised its position in Kenvue by 3.5% in the first quarter. Alley Investment Management Company LLC now owns 263,569 shares of the company’s stock worth $6,320,000 after purchasing an additional 8,988 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.